Logo

First Genetic Trust Closing on $5.5 Million Series C Financing

Sep 24, 2003

NEW YORK, Sept. 24 (GenomeWeb News) -- First Genetic Trust today announced the closing of a $5.5 million Series C round of financing.

 

The venture capital firms of Venrock Associates of New York and ARCH Venture Partners of Chicago led the funding for the Deefield, Ill.-based information technology firm that offers security products and services for genetic data. Additional investors include Cooper Hill Partners of New York, a healthcare investor, and the development and services firm, Quintiles Transnational of Durham, NC.

 

First Genetic Trust took a $15.6 million first round of financing on Sept. 30, 2000, and followed with a $12.2 million round in February 2001.

 

The funds raised will support further commercialization of the Company's enTRUST genetic study and banking technology into the pharmaceutical, academic and government markets, First Genetic Trust said in a statement.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.